Onset of Preclinical Alzheimer Disease in Monozygotic Twins
Overview
Authors
Affiliations
Objective: The present work was undertaken to study the genetic contribution to the start of Alzheimer's disease (AD) with amyloid and tau biomarkers in cognitively intact older identical twins.
Methods: We studied in 96 monozygotic twin-pairs relationships between amyloid-beta (Aβ) aggregation as measured by the Aβ1-42/1-40 ratio in cerebrospinal fluid (CSF; n = 126) and positron emission tomography (PET, n = 194), and CSF markers for Aβ production (beta-secretase 1, Aβ1-40, and Aβ1-38) and CSF tau. Associations among markers were tested with generalized estimating equations including a random effect for twin status, adjusted for age, gender, and apolipoprotein E ε4 genotype. We used twin analyses to determine relative contributions of genetic and/or environmental factors to AD pathophysiological processes.
Results: Twenty-seven individuals (14%) had an abnormal amyloid PET, and 14 twin-pairs (15%) showed discordant amyloid PET scans. Within twin-pairs, Aβ production markers and total-tau (t-tau) levels strongly correlated (r range = 0.73-0.86, all p < 0.0001), and Aβ aggregation markers and 181-phosphorylated-tau (p-tau) levels correlated moderately strongly (r range = 0.50-0.64, all p < 0.0001). Cross-twin cross-trait analysis showed that Aβ1-38 in one twin correlated with Aβ1-42/1-40 ratios, and t-tau and p-tau levels in their cotwins (r range = -0.28 to 0.58, all p < .007). Within-pair differences in Aβ production markers related to differences in tau levels (r range = 0.49-0.61, all p < 0.0001). Twin discordance analyses suggest that Aβ production and tau levels show coordinated increases in very early AD.
Interpretation: Our results suggest a substantial genetic/shared environmental background contributes to both Aβ and tau increases, suggesting that modulation of environmental risk factors may aid in delaying the onset of AD pathophysiological processes. ANN NEUROL 2021;89:987-1000.
Contributions of amyloid beta and cerebral small vessel disease in clinical decline.
Moonen J, Haan R, Bos I, Teunissen C, van de Giessen E, Tomassen J Alzheimers Dement. 2023; 20(3):1868-1880.
PMID: 38146222 PMC: 10984432. DOI: 10.1002/alz.13607.
Gillespie N, Elman J, McKenzie R, Tu X, Xian H, Reynolds C Alzheimers Dement. 2023; 20(1):356-365.
PMID: 37622539 PMC: 10843753. DOI: 10.1002/alz.13407.
A Rare Case of Postoperative Encephalopathy in Twin.
Huang C, Casey C, Ismael H Cureus. 2023; 15(4):e37610.
PMID: 37197100 PMC: 10184516. DOI: 10.7759/cureus.37610.
Genetically identical twin-pair difference models support the amyloid cascade hypothesis.
Coomans E, Tomassen J, Ossenkoppele R, Tijms B, Lorenzini L, Ten Kate M Brain. 2023; 146(9):3735-3746.
PMID: 36892415 PMC: 10473566. DOI: 10.1093/brain/awad077.
Histone Modifications in Alzheimer's Disease.
Santana D, Smith M, Chen E Genes (Basel). 2023; 14(2).
PMID: 36833274 PMC: 9956192. DOI: 10.3390/genes14020347.